Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or VSports app下载. mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

Review
. 2020 May 27:8:18.
doi: 10.1186/s40364-020-00197-1. eCollection 2020.

V体育安卓版 - Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies

Yuru Nie #  1 , Weiqing Lu #  1 , Daiyu Chen #  1 , Huilin Tu  1 , Zhenling Guo  2 , Xuan Zhou  2 , Meifang Li  2 , Sanfang Tu  2 , Yuhua Li  2
Affiliations
Review

Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies

Yuru Nie et al. Biomark Res. .

Abstract

Chimeric antigen receptor (CAR) T cell therapy, especially anti-CD19 CAR T cell therapy, has shown remarkable anticancer activity in patients with relapsed/refractory acute lymphoblastic leukemia, demonstrating an inspiring complete remission rate. However, with extension of the follow-up period, the limitations of this therapy have gradually emerged. Patients are at a high risk of early relapse after achieving complete remission. Although there are many studies with a primary focus on the mechanisms underlying CD19- relapse related to immune escape, early CD19+ relapse owing to poor in vivo persistence and impaired efficacy accounts for a larger proportion of the high relapse rate. However, the mechanisms underlying CD19+ relapse are still poorly understood. Herein, we discuss factors that could become obstacles to improved persistence and efficacy of CAR T cells during production, preinfusion processing, and in vivo interactions in detail. Furthermore, we propose potential strategies to overcome these barriers to achieve a reduced CD19+ relapse rate and produce prolonged survival in patients after CAR T cell therapy VSports手机版. .

Keywords: Acute lymphocytic leukemia (ALL); CAR T cell therapy; Chimeric antigen receptor; Mechanism; Positive relapse; Strategy V体育安卓版. .

PubMed Disclaimer

VSports注册入口 - Conflict of interest statement

Competing interestsThe authors declare that they have no conflicts of interest.

V体育安卓版 - Figures

Fig. 1
Fig. 1
Factors influencing CD19 CAR T cell therapy. The limited persistence and impaired efficacy of CAR T cells could be possible mechanisms underlying CD19+ relapse. This figure summarizes potential obstacles to durable remission and better CAR T cell efficacy. First, T cell collection: T cells selected for manufacturing should be of sufficient quantity and good quality and have a phenotype with memory characteristics. Second, CAR T cell manufacture: transgene rejection induced by a murine scFv results in transient in vivo persistence. Selection of the costimulatory domain, transduction technique, especially vector selection, and proliferation method also plays roles in persistence and efficacy. Third, preinfusion: the tumor burden before infusion is associated with patient long-term survival. In addition to lymphodepleting therapy, a conditioning regimen with fludarabine ameliorates T cell persistence. Finally, postinfusion: normal B cells are supposed to recover, but transient B cell aplasia may result in CD19+ relapse. Aberrant signaling pathways and the BM microenvironment will impair a T cell’s potential along with its in vivo persistence
Fig. 2
Fig. 2
Main signaling pathways involved in CD19-BBζ T cells and CD19-28ζ T cells. a A high mitochondrial respiratory capacity promotes metabolism and differentiation. 4-1BB domain signaling activates the PI3K pathway and upregulates Bcl-xL and BFL-1 expression. Tonic CAR-derived 4-1BB signaling activates the NF-B pathway and enhances FAS-dependent apoptosis. CD19-BBζ T cells diminish the expression of exhaustion-associated molecules more than CD19-28ζ T cells. b The main signaling pathways involved in CD19-28ζ T cells. CAR T cell inhibition induced by regulatory T cells, IL-10 and TGF-β can be reduced by the incorporation of the CD28 domain. CD19-28ζ T cells exhibit enhanced activation of the transcription factor NF-B and promote cytokine secretion. CD19-28ζ T cells are more likely to result in the development of severe CRS than CD19-BBζ T cells. However, tonic CAR CD3ζ phosphorylation triggered by clustering of the CAR single-chain variable fragment (scFv) leads to more rapid exhaustion
Fig. 3
Fig. 3
The mechanism of CD19+ relapse in BM microenvironment. a Main interaction between negative regulatory cells, tumor cells and immune effector cells in BM microenvironment. Tregs, MDSCs and TAMs suppress CTLs, DCs, NK cells and T cells by cytokines, enzymes and cell-cell interactions. Negative regulatory cells and tumor cells attract and improve each other’s recruitment, differentiation and expansion. Tregs: regulatory T cells; MDSCs: myeloid-derived suppressor cells; TAMs: tumor associated macrophages; IDO: indoleamine-2, 3-dioxygenase; CTLs: cytotoxic T cells; DCs: dendritic cells; NK cells: natural kill cells; TGF-β: transforming growth factor β. b The negative regulation checkpoint in BM microenvironment. The PD-1/PD-L1 pathway between tumor cells and MDSCs, T cells, TAMs inhibits the proliferating of T cells and transforms T cells into induces Tregs or induces apoptosis. The CTLA-4/B7 pathway suppresses APCs while activates Tregs. (Tregs: regulatory T cells; iTregs: induced Tregs; TAMs: tumor associated macrophages; APCs: antigen-presenting cells; MDSCs: myeloid-derived suppressor cells; PD-1: programmed death-1; PD-L: programmed cell death 1 ligand)
Fig. 4.
Fig. 4.
Some key points during the process of manufacturing CAR T cells. a The progress of T cells with the associated characteristics. As TN cells differentiate, the proliferative capacity of T cells is gradually reduced. Except for TE cells, the remaining subsets have a self-renewal ability, which declines from TN to TEM cells. Therefore, it is best to choose TSCM cells for CAR T cell generation. b Adding IL-7/IL-15 during in vitro expansion has a positive impact. IL-7/IL-15 can increase the proportion of TSCM cells and contribute to maintaining the ratio of CD4+:CD8+ cells.
See this image and copyright information in PMC

"V体育2025版" References

    1. Liu D. CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy. J Hematol Oncol. 2019;12(1):113. - PMC - PubMed
    1. Hartmann J, Schussler-Lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 2017;9(9):1183–1197. - PMC - PubMed
    1. June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–1365. - PubMed
    1. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–1518. - PMC - PubMed
    1. Rosenbaum L. Tragedy, Perseverance, and Chance - The Story of CAR-T Therapy. N Engl J Med. 2017;377(14):1313–1315. - PubMed

VSports - LinkOut - more resources